Kohlberg Kravis Roberts & Co. L.P.

13F Filings History

Latest 13F report
Q3 2024 - Nov 14, 2024
Value $
$7.47B
Signature - Title
Lew Breckenridge - Managing Director
Location
New York, NY
Summary
This page shows a list of all the recent 13F filings made by Kohlberg Kravis Roberts & Co. L.P.. Form 13F is required to be filed within 45 days of the end of a calendar quarter. Kohlberg Kravis Roberts & Co. L.P. reported 72 stock holdings with total value $7.47B as of Q3 2024. Top holdings included OS, BTSG, BBIO, BV, and PGRU.
Holdings Value
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Date Filed
Q3 2024 72 $7.47B +$3.95B -$340M +$3.61B OS, BTSG, BBIO, BV, PGRU 13F-HR 11/14/2024, 03:01 PM
Q2 2024 69 $3.33B +$165M -$650M -$484M BTSG, BBIO, BV, PGRU, KREF 13F-HR 8/14/2024, 04:55 PM
Q1 2024 67 $3.88B +$1.04B -$650M +$393M BBIO, BTSG, BV, PGRU, TGAN 13F-HR 5/15/2024, 03:54 PM
Q4 2023 71 $3.38B +$128M -$170M -$41M BBIO, BV, FSK, APP, PGRU 13F-HR 2/14/2024, 02:39 PM
Q3 2023 73 $2.85B +$148M -$1.15B -$1B BBIO, BV, FSK, APP, PGRU Restatement 1/22/2024, 10:27 AM
Q2 2023 71 $3.23B +$135M -$932M -$797M APP, BBIO, FSK, BV, PGRU 13F-HR 8/14/2023, 10:35 AM
Q1 2023 82 $3.32B +$88.4M -$283M -$195M APP, BBIO, FSK, BV, PGRU 13F-HR 5/15/2023, 03:42 PM
Q4 2022 126 $2.96B +$155M -$1.53B -$1.37B APP, BV, FSK, BBIO, EDR 13F-HR 2/14/2023, 12:08 PM
Q3 2022 213 $4.98B +$66.2M -$1.61B -$1.55B APP, FI, BV, LAUR, FSK 13F-HR 11/14/2022, 10:08 AM
Q2 2022 263 $7.52B +$169M -$1.28B -$1.11B FI, APP, BV, FSK, LAUR 13F-HR 8/12/2022, 04:12 PM
Q1 2022 276 $11B +$920M -$3.76B -$2.84B APP, FI, BV, FSK, EDR 13F-HR 5/16/2022, 04:48 PM
Q4 2021 208 $18.2B +$547M -$3.39B -$2.85B APP, FI, EDR, BV, KNBE 13F-HR 2/14/2022, 02:09 PM
Q3 2021 185 $19.9B +$390M -$4.18B -$3.79B APP, FI, BBIO, BV, KNBE 13F-HR 11/15/2021, 05:07 PM
Q2 2021 141 $24.7B +$10.5B -$5.33B +$5.15B APP, FI, BBIO, IR, ASO 13F-HR 8/16/2021, 02:14 PM
Q1 2021 101 $19.8B +$376M -$1.41B -$1.03B FI, IR, BBIO, ASO, BV 13F-HR 5/17/2021, 04:41 PM
Q4 2020 60 $19.7B +$1.51B -$2.77B -$1.26B FI, BBIO, IR, ASO, BV 13F-HR 2/16/2021, 05:01 PM
Q3 2020 65 $17.3B +$608M -$930M -$322M FI, IR, BBIO, BV, KREF 13F-HR 11/16/2020, 05:00 PM
Q2 2020 67 $16.3B +$711M -$1.1B -$387M FI, IR, BBIO, BV, KREF 13F-HR 8/14/2020, 05:02 PM
Q1 2020 50 $15.7B +$1.97B -$3.11B -$1.14B FI, IR, BBIO, BV, KREF 13F-HR 5/15/2020, 05:19 PM
Q4 2019 54 $20.5B +$363M -$310M +$53.3M FI, GDI, BBIO, BV, KREF 13F-HR 2/14/2020, 04:01 PM
Q3 2019 52 $17.8B +$11.7B -$1.26B +$10.4B FI, GDI, BV, BBIO, KREF 13F-HR 11/14/2019, 04:02 PM
Q2 2019 55 $8.12B +$1.22B -$300M +$925M GDI, BV, BBIO, PRAH, KREF 13F-HR 8/14/2019, 04:00 PM
Q1 2019 55 $6.57B +$749M -$733M +$16.1M GDI, BV, PRAH, KREF, FOCS 13F-HR 5/15/2019, 04:01 PM
Q4 2018 56 $5.48B +$537M -$1.64B -$1.1B GDI, PRAH, BV, KREF, EYE 13F-HR 2/13/2019, 04:06 PM
Q3 2018 57 $8.81B +$1.4B -$1.82B -$425M GDI, BV, EYE, PRAH, KREF 13F-HR 11/14/2018, 04:03 PM
Q2 2018 51 $8.78B +$1.84B -$1.62B +$223M GDI, BV, PRAH, EYE, KREF 13F-HR 8/14/2018, 04:02 PM
Q1 2018 42 $8.22B +$228M -$1.4B -$1.17B GDI, PRAH, EYE, KREF, GDDY 13F-HR 5/15/2018, 04:05 PM
Q4 2017 49 $10.1B +$2.32B -$1.91B +$408M GDI, EYE, PRAH, KREF, GDDY 13F-HR 2/14/2018, 04:30 PM
Q3 2017 1 $73.5M $0 $0 WRD New Holdings 2/14/2018, 04:37 PM
Q3 2017 51 $8.65B +$352M -$1.5B -$1.15B GDI, PRAH, USFD, KREF, GDDY 13F-HR 11/14/2017, 04:23 PM
Q2 2017 1 $68.3M $0 $0 WRD New Holdings 2/14/2018, 04:25 PM
Q2 2017 2 $511M $0 $0 KREF, VRS New Holdings 11/14/2017, 04:15 PM
Q2 2017 47 $8.83B +$4.1B -$1.11B +$2.99B GDI, PRAH, USFD, KREF, GDDY 13F-HR 8/14/2017, 04:05 PM
Q1 2017 1 $60K $0 $0 VRS New Holdings 11/14/2017, 04:08 PM
Q1 2017 1 $9.79M $0 $0 NOMD New Holdings 6/29/2017, 05:00 PM
Q1 2017 50 $5.56B +$289M -$1.37B -$1.08B USFD, PRAH, GDDY, EGL, AMED 13F-HR 5/15/2017, 04:32 PM
Q4 2016 1 $71K $0 $0 VRS New Holdings 11/14/2017, 04:05 PM
Q4 2016 53 $6.26B +$615M -$2.7B -$2.08B USFD, PRAH, GDDY, HCA, EGL 13F-HR 2/14/2017, 04:33 PM
Q3 2016 1 $65K $0 $0 VRS New Holdings 11/14/2017, 04:02 PM
Q3 2016 55 $8.03B +$497M -$2.32B -$1.82B USFD, WBA, PRAH, GDDY, HCA 13F-HR 11/14/2016, 04:46 PM
Q2 2016 49 $9.37B +$2.56B -$3.24B -$673M WBA, USFD, PRAH, GDDY, ZBH 13F-HR 8/15/2016, 05:11 PM
Q1 2016 50 $10.1B +$304M -$414M -$110M WBA, PRAH, HCA, ZBH, GDDY 13F-HR 5/16/2016, 05:23 PM
Q4 2015 54 $10.3B +$881M -$472M +$409M WBA, PRAH, HCA, ZBH, GDDY Restatement 4/1/2016, 05:18 PM
Q3 2015 67 $9.4B +$461M -$1.59B -$1.13B WBA, PRAH, HCA, ZBH, GDDY Restatement 4/1/2016, 05:07 PM
Q2 2015 56 $11.1B +$1.72B -$725M +$1B WBA, PRAH, HCA, SJM, ZBH Restatement 4/1/2016, 05:05 PM
Q1 2015 84 $9.61B +$1.82B -$387M +$1.43B WBA, PRAH, HCA, SJM, NLSN 13F-HR 5/15/2015, 04:49 PM
Q4 2014 74 $7.63B +$5.09B -$882M +$4.21B WBA, HCA, PRAH, NLSN, RNET 13F-HR 2/17/2015, 05:04 PM
Q3 2014 82 $3.32B +$506M -$486M +$20M HCA, NLSN, WAG, RNET, KKR 13F-HR 11/14/2014, 05:22 PM
Q2 2014 75 $3.38B +$462M -$3.03B -$2.57B HCA, NLSN, WAG, RNET, KKR 13F-HR 8/14/2014, 04:38 PM
Q1 2014 129 $5.75B +$1.04B -$1.54B -$503M HCA, NLSN, MRVL, NXPI, WAG Restatement 8/14/2014, 04:33 PM
Q4 2013 115 $5.83B $0 $0 HCA, NLSN, NXPI, MRVL, JAZZ 13F-HR 2/14/2014, 04:20 PM